Genetic polymorphisms may contribute to the abnormalities noted in nonlesional skin, as, for example, susceptibility to lupus is in part associated with polymorphisms in the IL-21 axis (40) and polymorphisms in IL-17 are correlated with PSO treatment response (41). Here, IL17A is linked to systemic lupus erythematosus.